FRAMINGHAM, Mass., Aug. 5, 2014 /PRNewswire/ -- HeartWare
International, Inc. (NASDAQ:HTWR), a leading innovator of less
invasive, miniaturized circulatory support technologies that are
revolutionizing the treatment of advanced heart failure, today
announced that CEO Doug Godshall is
scheduled to present at the Canaccord Genuity 34th Annual Growth
Conference at 9:00 a.m. EDT on
Thursday, August 14, 2014. The
conference is being held August 13-14
at the InterContinental Boston.
A live webcast of the Company's presentation at the conference
will be available via a link provided at www.heartware.com. A
replay of the webcast will be available for 90 days at the site
after the presentation.
About HeartWare International
HeartWare International develops and manufactures miniaturized
implantable heart pumps, or ventricular assist devices, to treat
Class IIIB / IV patients suffering from advanced heart
failure. The HeartWare® Ventricular Assist System
features the HVAD® pump, a small full-support
circulatory assist device designed to be implanted next to the
heart, avoiding the abdominal surgery generally required to implant
competing devices. The HeartWare System is approved in the United States for the intended use as a
bridge to cardiac transplantation in patients who are at risk of
death from refractory end-stage left ventricular heart failure, has
received CE Marking in the European Union and has been used to
treat patients in 40 countries. The device is also currently the
subject of a U.S. clinical trial for destination therapy. For
additional information, please visit the Company's website at
www.heartware.com.
HeartWare International, Inc. is a member of the Russell
2000® and its securities are publicly traded on The
NASDAQ Stock Market.
HEARTWARE, HVAD, MVAD, PAL, SYNERGY, CIRCULITE and HeartWare
logos are registered trademarks of HeartWare, Inc.
For further information:
Christopher Taylor
HeartWare International, Inc.
Email: ctaylor@heartware.com
Phone: +1 508 739 0864
SOURCE HeartWare International, Inc.